Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UL01
UPID:
DSE_HUMAN
Alternative names:
Chondroitin-glucuronate 5-epimerase; Squamous cell carcinoma antigen recognized by T-cells 2
Alternative UPACC:
Q9UL01; Q5R3K6
Background:
Dermatan-sulfate epimerase, also known as Chondroitin-glucuronate 5-epimerase and recognized by T-cells as Squamous cell carcinoma antigen 2, plays a pivotal role in converting D-glucuronic acid to L-iduronic acid. This enzymatic activity is crucial for the biosynthesis of dermatan sulfate, a type of glycosaminoglycan/mucopolysaccharide essential for various biological processes.
Therapeutic significance:
The protein's malfunction is linked to Ehlers-Danlos syndrome, musculocontractural type 2, characterized by joint dislocations, skin fragility, and multisystem complications. Understanding Dermatan-sulfate epimerase's role could unveil new therapeutic strategies for this and potentially other related disorders.